Exchange: NASDAQ·Updated 03:37 PM EDT
News
all
press releases
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints
CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential...
PR Newswire
More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 million. CalciMedica (NASDAQ:CALC) shares rose 9.8%read more...
Benzinga
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program PR Newswire LA JOLLA, Calif., June 24, 2026...
PR Newswire
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data PR Newswire LA JOLLA, Calif., June 24, 2026 FDA...
PR Newswire
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates...
PR Newswire
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates CalciMedica Reports 2025 Financial Results and Provides Clinical Updates PR Newswire LA JOLLA, Calif., March 3, 2026 Internal...
PR Newswire
How Is The Market Feeling About CalciMedica Inc?
read more...
Benzinga
CALC Stock Slumped 76% On Wednesday — Here’s Why
CalciMedica said that it has decided to discontinue the trial evaluating its lead product candidate Auxora in patients with Stage 2 or Stage 3 acute kidney injury following a committee recommendation.
Stocktwits
CalciMedica (NASDAQ:CALC) Upgraded to Sell at Wall Street Zen
Wall Street Zen upgraded CalciMedica to a "sell" rating in a report on Saturday...
MarketBeat
CalciMedica (NASDAQ:CALC) Trading Down 2.1% - Time to Sell?
CalciMedica (NASDAQ:CALC) Stock Price Down 2.1% - Time to Sell...
MarketBeat

Advertisement|Remove ads.